X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The financing will be used to advance the Company’s preclinical pipeline, including a TROP2-TRACTr and PSMA-TRACTr, with expected advancement of the Company’s first candidate into the clinic in the first half of next year.
Lead Product(s): TROP2-TRACTr based therapeutics
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Janux Therapeutics
Deal Size: $56.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing March 03, 2021
Details:
Avalon is expanding its AVA-001 clinical trial to recruit patients with relapsed/refractory Non-Hodgkin lymphoma (R/R-NHL).
Lead Product(s): CD19-CAR-T cells
Therapeutic Area: Oncology Product Name: AVA-001
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 01, 2020
Details:
Completed Phase I Clinical Study of 4-1BB Based Anti-CD19 CAR-T Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia; Achieved 90% Complete Remission (CR) Rate with Minimum Toxicity or Adverse Side Effects.
Lead Product(s): AVA-001,Fludarabine Phosphate,Cyclophosphamide
Therapeutic Area: Oncology Product Name: AVA-001
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2020
Details:
Nine out of ten patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) have achieved complete remission (CR rate of 90%) within one month after the initiation of AVA-001 CAR T-cell therapy treatment.
Lead Product(s): AVA-001,Fludarabine Phosphate,Cyclophosphamide
Therapeutic Area: Oncology Product Name: AVA-001
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2020
Details:
Avalon forms strategic partnership with the University of Natural Resources and Life Sciences (BOKU) in Vienna, Austria and the nanotechnology laboratory of Professor Uwe B. Sleytr on a novel S-layer SARS-CoV-2 (COVID-19) vaccine.
Lead Product(s): S-layer COVID vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Vaccine
Partner/Sponsor/Collaborator: University of Natural Resources
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 25, 2020
Details:
Avalon’s AVA-Trap™ therapeutic program is currently entering animal model testing followed by expedited clinical studies with the goal of providing an effective therapeutic option to combat COVID-19.
Lead Product(s): AVA-Trap
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
